We place a high priority on providing more treatment options for our patients, to give them a better chance against the disease than just the current standard of care. That’s why all physicians in our Lymphoma Service are also research scientists who are actively engaged in basic (laboratory) research, clinical research (involving patients) and translational research (which helps speed laboratory discoveries to the clinic).
Our work focuses on better understanding how lymphoma begins and how to estimate a patient’s chance of recovery, and identifying cellular and molecular features linked to treatment resistance in all types of lymphoid malignancies.
Some of our current work in lymphoma involves:
- Developing new drugs, such as drugs that block key enzymes in lymphoma cells
- Improving the effectiveness of monoclonal antibodies and other drug conjugates against lymphoma
- Creating strategies for overcoming rituximab-chemotherapy resistance in B-cell and T-cell lymphomas
- Finding new ways to use existing cancer drugs or therapies, including combinations of chemotherapies, targeted therapies and radiation
- Searching for new targets or pathways to attack the cancer
- Understanding how lymphomas grow and spread, so we can find ways to stop them.
- Identifying biomarkers to help us predict patients’ response to specific therapies for Hodgkin or non-Hodgkin lymphoma
- Using information acquired in the laboratory to design novel clinical trials for lymphoma patients